TITLE

Murine Monoclonal Antibodies Biologically Active against the Amino Region of HIV-1 gp120: Isolation and Characterization

AUTHOR(S)
Dickey, Chad; Ziegner, Ulrike; Agadjanyan, P Michael G.; Srikantan, Vasantha; Refaeli, Yosef; Prabhu, Ashwin; Sato, Alice; Williams, William V.; Weiner, David B.; Ugen, Kenneth E.
PUB. DATE
April 2000
SOURCE
DNA & Cell Biology;Apr2000, Vol. 19 Issue 4, p243
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The human immunodeficiency virus (HIV)-1 envelope glycoprotein is synthesized as a precursor (gp160) and subsequently cleaved to generate the external gp120 and transmembrane gp41 glycoproteins. Both gp120 and gp41 have been demonstrated to mediate critical functions of HIV, including viral attachment and fusion with the cell membrane. The antigenic variability of the HIV-1 envelope glycoprotein has presented a significant problem in the design of appropriate and successful vaccines and offers one explanation for the ability of HIV to evade immune surveillance. Therefore, the development and characterization of functional antibodies against conserved regions of the envelope glycoprotein is needed. Because of this need, we generated a panel of murine monoclonal antibodies (MuMabs) against the HIV-1 envelope glycoprotein. To accomplish this, we immunized Balb/C mice with a recombinant glycoprotein 160 (gp160) that was synthesized in a baculovirus expression system. From the growth-positive hybridomas, three MuMabs were generated that demonstrated significant reactivity with recombinant gp120 but failed to show reactivity against HIV-1 gp41, as determined by enzyme-linked immunosorbent assay (ELISA). Using vaccinia constructs that synthesize variant truncated subunits of gp160, we were able to map reactivity of all three of the Mabs (ID6, AC4, and AD3) to the first 204 residues of gp120 (i.e., the N terminus of gp120) via Western blot analysis. Elucidation of the epitopes for these Mabs may have important implications for inhibition of infection by HIV-1. Our initial attempts to map these Mabs with linear epitopes have not elucidated a specific antigenic determinant; however, several physical characteristics have been determined that suggest a continuous surface epitope. Although these antibodies failed to neutralize cell-free or cell-associated infection by HIV-1, they did mediate significant antibodydependent cellular cytotoxity (ADCC) activity, indicating potential therapeutic utility. In summary, these data suggest the identification of a potentially novel site in the first 200 aa of gp120 that mediates ADCC.
ACCESSION #
5322739

 

Related Articles

  • A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Wenbo Wang; Jianhui Nie; Prochnow, Courtney; Truong, Carolyn; Zheng Jia; Suting Wang; Xiaojiang S. Chen; Youchun Wang // Retrovirology;2013, Vol. 10 Issue 1, p1 

    Background: Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated...

  • Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Song, Ruijiang; Oren, Deena A; Franco, David; Seaman, Michael S; Ho, David D // Nature Biotechnology;Nov2013, Vol. 31 Issue 11, p1047 

    Ibalizumab is a humanized monoclonal antibody that binds human CD4-a key receptor for HIV-and blocks HIV-1 infection. However, HIV-1 strains with mutations resulting in loss of an N-linked glycan from the V5 loop of the envelope glycoprotein gp120 are resistant to ibalizumab. Previous structural...

  • A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. Sanders, Rogier W.; Derking, Ronald; Cupo, Albert; Julien, Jean-Philippe; Yasmeen, Anila; de Val, Natalia; Kim, Helen J.; Blattner, Claudia; de la Peña, Alba Torrents; Korzun, Jacob; Golabek, Michael; de los Reyes, Kevin; Ketas, Thomas J.; van Gils, Marit J.; King, C. Richter; Wilson, Ian A.; Ward, Andrew B.; Klasse, P. J.; Moore, John P. // PLoS Pathogens;Sep2013, Vol. 9 Issue 9, p1 

    A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One approach to the problem is to create trimeric mimics of the native envelope glycoprotein (Env) spike that expose as...

  • MONOCLONAL ANTIBODY HAS EFFICACY AGAINST HIV.  // AIDS Patient Care & STDs;Jul99, Vol. 13 Issue 7, p438 

    Reports on the potent anti-HIV activity in a monoclonal antibody called PRO 140 that targets CCR5, the protein expressed on the surface of CD4 cells that serve as a target for HIV attachment and infection. Action of PRO 140 during the HIV replication cycle.

  • Cross-Neutralizing Human Monoclonal Anti-HIV-1 Antibody 2F5: Preparation and Crystallographic Analysis of the Free and Epitope-Complexed Forms of its F ab Fragment. Bryson, Steve; Cunningham, Annie; Ho, Jason; Hynes, Rosemary C.; Isenman, David E.; Barber, Brian H.; Kunert, Renate; Katinger, Hermann; Klein, Michel; Pai, Emil F. // Protein & Peptide Letters;Aug2001, Vol. 8 Issue 5, p413 

    The human monoclonal antibody 2F5 is a potent neutralizer of most clades of HIV-1 and possesses protective effects against viral transmission. It recognizes the linear epitope ELDKWAS of the viral envelope protein gp41. As structural information about epitope recognition may help to develop an...

  • Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian?human immunodeficiency virus infection. Baba, Timothy W.; Liska, Vladimir; Hofmann-Lehmann, Regina; Vlasak, Josef; Xu, Weidong; Ayehunie, Seyoum; Cavacini, Lisa A.; Posner, Marshall R.; Katinger, Hermann; Stiegler, Gabriela; Bernacky, Bruce J.; Rizvi, Tahir A.; Schmidt, Russell; Hill, Lori R.; Keeling, Michale E.; Lu, Yichen; Wright, Joel E.; Chou, Ting-Chao; Ruprecht, Ruth M. // Nature Medicine;Feb2000, Vol. 6 Issue 2, p200 

    Although maternal human immunodeficiency virus type 1 (HIV-1) transmission occurs during gestation, intrapartum and postpartum (by breast-feeding), 50-70% of all infected children seem to acquire HIV-1 shortly before or during delivery. Epidemiological evidence indicates that mucosal exposure is...

  • Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41. Khasawneh, Ashraf I.; Laumaea, Annemarie; Harrison, David N.; Bellamy-McIntyre, Anna K.; Drummer, Heidi E.; Poumbourios, Pantelis // Retrovirology;2013, Vol. 10 Issue 1, p1 

    Background: The disulfide-bonded region (DSR) of HIV-1 gp41 mediates association with gp120 and plays a role in transmission of receptor-induced conformational changes in gp120 to gp41 that activate membrane fusion function. In this study, forced viral evolution of a DSR mutant that sheds gp120...

  • Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies. Xiaodong Xiao; Weizao Chen; Yang Feng; Dimitrov, Dimiter S. // Viruses (1999-4915);Dec2009, Vol. 1 Issue 3, p802 

    Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized in terms of structure-function b12 and Fab X5, exhibit relatively potent and broad HIV-1 neutralizing activity. However, the elicitation of b12 or b12-like antibodies in vivo by vaccine...

  • Comparative Magnitude of Cross-Strain Conservation of HIV Variable Loop Neutralization Epitopes. Swetnam, James; Shmelkov, Evgeny; Zolla-Pazner, Susan; Cardozo, Timothy // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Although the sequence variable loops of the human immunodeficiency virus' (HIV-1) surface envelope glycoprotein (gp120) can exhibit good immunogenicity, characterizing conserved (invariant) cross-strain neutralization epitopes within these loops has proven difficult. We recently developed a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics